特宝生物公告，近日收到国家药品监督管理局核准签发的关于公司产品益佩生（通用名称：怡培生长激 素注射液）新增适应症"成人生长激素缺乏症（AGHD）"的《药物临床试验批准通知书》。益佩生是公 司自主研发的一款采用40kD Y型分支聚乙二醇进行单分子修饰的长效生长激素，是治疗用生物制品 1类 新药，其"适用于治疗 3 岁及以上儿童的生长激素缺乏症所致的生长缓慢"的适应症于 2025年 5月获批上 市，本次临床试验申请新增的适应症为"成人生长激素缺乏症（AGHD）"。 ...

Market Performance - The pharmaceutical sector experienced a slight decline of -0.07% on August 20, 2025, underperforming the CSI 300 index by 1.21 percentage points, ranking 31st among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, hospitals (+0.63%), blood products (+0.30%), and medical research outsourcing (+0.29%) showed positive performance, while other biopharmaceuticals (-1.02%), in vitro diagnostics (-0.46%), and medical consumables (-0.38%) lagged behind [1] - Top three gainers in individual stocks were Huabang Health (+10.11%), Jimin Health (+10.02%), and Tianmu Pharmaceutical (+10.01%), while the biggest losers were Xintian Pharmaceutical (-10.01%), Fuyuan Pharmaceutical (-10.00%), and Chengyi Pharmaceutical (-9.99%) [1] Industry News - Madrigal announced that the European Commission has conditionally approved its drug Rezdiffra (resmetirom) for treating adult patients with moderate to severe liver fibrosis due to non-alcoholic steatohepatitis (MASH) [2] - Resmetirom is a "first-in-class" oral thyroid hormone receptor (THR)-β selective agonist targeting the underlying causes of MASH [2] - This approval marks the first MASH therapy to receive EU approval, based on results from the pivotal MAESTRO-NASH Phase 3 clinical trial, which showed that 25.9% and 29.9% of patients in the 80mg and 100mg Resmetirom groups, respectively, achieved symptom resolution without worsening liver fibrosis at week 52, compared to 9.7% in the placebo group (P<0.001) [2] Company News - Heng Rui Medicine (600276) reported a revenue of 15.761 billion yuan for the first half of 2025, a year-on-year increase of 15.88%, with a net profit attributable to shareholders of 4.450 billion yuan, up 29.67% [3] - Lizhu Group (000513) posted a revenue of 6.272 billion yuan for the first half of 2025, a slight decline of 0.17%, while net profit attributable to shareholders increased by 9.40% to 1.281 billion yuan [3] - Te Bao Biological (688278) achieved a revenue of 1.511 billion yuan, reflecting a growth of 26.96%, with a net profit of 428 million yuan, up 40.60% [3] - Zhong Yao Holdings (000950) reported a revenue of 41.188 billion yuan, a growth of 3.54%, and a net profit of 282 million yuan, increasing by 18.56% [3]

Core Insights - The company reported strong growth in its semi-annual report, with a revenue of 1.511 billion yuan, representing a year-on-year increase of 26.96%, and a net profit of 428 million yuan, up 40.60% [1] - The core product, Pegbivac, has gained recognition for its effectiveness in improving clinical cure rates for chronic hepatitis B and significantly reducing the risk of liver cancer, driving both revenue and profit growth [1] Financial Performance - In the first half of 2025, the company achieved a record high in both revenue and net profit, with revenue reaching 1.511 billion yuan and net profit at 428 million yuan [1] - The growth rates of 26.96% in revenue and 40.60% in net profit indicate robust financial health and operational efficiency [1] Market Context - China has approximately 75 million chronic hepatitis B virus carriers, with 20 to 30 million suffering from chronic hepatitis B, highlighting a significant market opportunity for the company's products [1] - The annual incidence rate of liver cirrhosis among chronic hepatitis B patients is between 2% and 10%, and the progression from cirrhosis to liver cancer has an annual incidence rate of 3% to 6%, underscoring the critical need for effective treatments [1] Research and Development Initiatives - The company is actively involved in various public welfare and research projects aimed at hepatitis B clinical cure and liver cancer prevention, including the "Everest" project, which is the largest real-world study on chronic hepatitis B [2] - As of May 2025, the "Everest" project has enrolled 33,466 patients and achieved surface antigen clearance in 10,240 cases, with a clearance rate exceeding 30% for patients treated for over 36 weeks [2] Technological Advancements - The company has developed three core technology platforms related to polyethylene glycol (PEG) modification, protein drug production, and drug screening and optimization, establishing itself as a leader in the PEG long-acting protein field in China [3] - The recent approval of a new long-acting growth hormone, Yipeisheng, for treating growth hormone deficiency in children, positions the company to capture a share of the growing growth hormone market, projected to reach 28.6 billion yuan by 2030 [3] Future Outlook - The company plans to continue focusing on the fields of immunology and metabolism, accelerating innovation to produce more "China-made" products and services for human health [3]

Core Viewpoint - As of August 20, a total of 119 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Jichuan Pharmaceutical, which has seen net buying for 15 consecutive trading days [1] - Other notable stocks with significant net buying days include Suzhou Bank, ST Guangwu, Te Bao Biological, Jinmoly Co., Ningbo Fuda, Dong'a Ejiao, Xidamen, and China Power [1]

Core Insights - The company reported a total revenue of 1.511 billion yuan and a net profit attributable to shareholders of 428 million yuan for the first half of 2025 [2] - The operating cash flow net inflow was 361 million yuan [2] Financial Metrics - The latest debt-to-asset ratio is 14.15%, which is an increase of 0.62 percentage points compared to the previous quarter [4] - The latest gross profit margin is 92.98%, a decrease of 0.19 percentage points from the previous quarter and a decrease of 0.38 percentage points year-on-year [4] - The latest return on equity (ROE) is 15.53% [4] Earnings and Efficiency Ratios - The diluted earnings per share (EPS) is 1.05 yuan [5] - The total asset turnover ratio is 0.48 times, a decrease of 0.02 times compared to the same period last year, representing a year-on-year decline of 3.44% [5] - The inventory turnover ratio is 0.36 times, a decrease of 0.02 times compared to the same period last year, representing a year-on-year decline of 4.20% [5] Shareholder Structure - The number of shareholders is 8,439, with the top ten shareholders holding 282 million shares, accounting for 69.44% of the total share capital [5] - The largest shareholder is Yang Ying, holding 33.94% of the shares [5]

公司股东户数为8439户，前十大股东持股数量为2.82亿股，占总股本比例为69.44%，前十大股东持股情 况如下： 2025年8月21日，特宝生物(688278.SH)发布2025年中报。 公司最新资产负债率为14.15%，较去年同期资产负债率减少2.11个百分点。 公司最新毛利率为92.98%。最新ROE为15.53%，较去年同期ROE增加0.42个百分点。 公司摊薄每股收益为1.05元，较去年同报告期摊薄每股收益增加0.30元，实现5年连续上涨，同比较去年 同期上涨40.00%。 公司最新总资产周转率为0.48次。最新存货周转率为0.36次。 公司营业总收入为15.11亿元，较去年同报告期营业总收入增加3.21亿元，实现5年连续上涨，同比较去 年同期上涨26.96%。归母净利润为4.28亿元，较去年同报告期归母净利润增加1.24亿元，实现5年连续 上涨，同比较去年同期上涨40.60%。经营活动现金净流入为3.61亿元，较去年同报告期经营活动现金净 流入增加2.88亿元，实现2年连续上涨，同比较去年同期上涨397.97%。 | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | ...

2025年8月21日，特宝生物(688278.SH)发布2025年半年度报告。截至2025年8月20日，共有20个机构投 资者披露持有特宝生物A股股份，合计持股量达8319.11万股，占特宝生物总股本的20.45%。其中，前 十大机构投资者包括通化东宝药业股份有限公司、招商银行股份有限公司-华夏上证科创板50成份交易 型开放式指数证券投资基金、中国工商银行股份有限公司-易方达上证科创板50成份交易型开放式指数 证券投资基金、东方红睿丰混合、信澳健康中国混合A、天弘中证医药100A、汇丰晋信医疗先锋混合 A、招商均衡成长混合A、宏利红利先锋混合A、宏利医药健康混合发起A，前十大机构投资者合计持股 比例达20.42%。相较于上一季度，前十大机构持股比例合计下跌了5.57个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计5个，包括华夏上证科创板50成份ETF、易方达 上证科创板50ETF、招商均衡成长混合A、宏利红利先锋混合A、宏利医药健康混合发起A，持股增加占 比达0.26%。本期较上一季度持股减少的公募基金共计5个，包括信澳健康中国混合A、宏利逆向策略混 合、天弘中证医药100A、华商创新医疗混合A、 ...

Core Viewpoint - The company has released its 2025 semi-annual report, which reflects its financial status and operational performance, ensuring compliance with relevant regulations and internal procedures [8][9]. Group 1: Company Overview - The company is identified as Xiamen Te Bao Biological Engineering Co., Ltd., with stock code 688278 [12]. - The semi-annual report is unaudited and emphasizes the importance of reading the full report for a comprehensive understanding of the company's performance [4][1]. Group 2: Financial Data - The total amount raised from the initial public offering was RMB 383.16 million, with a net amount of RMB 330.45 million after deducting issuance costs [13]. - As of June 30, 2025, the company has utilized RMB 0.304 million in the current year and a cumulative total of RMB 385.13 million from the raised funds [15]. Group 3: Fund Management - The company has established a fundraising management system to ensure the proper use and management of raised funds, adhering to legal and regulatory requirements [16]. - A tripartite supervision agreement was signed with the sponsor and the bank for the storage of raised funds, ensuring compliance with the agreement [17]. Group 4: Fund Usage and Adjustments - The company has not used idle raised funds for temporary working capital or cash management during the reporting period [20][21]. - There was an adjustment in the investment amounts for specific projects, with the protein drug production project receiving an increase from RMB 159.40 million to RMB 199.40 million [26].

证券日报网讯 8月20日晚间，特宝生物发布公告称，2025年半年度公司实现营业收入1，510，615， 117.77元，同比增长26.96%；归属于上市公司股东的净利润为427，894，111.21元，同比增长40.60%。 （编辑 何成浩） ...

（编辑 任世碧） 证券日报网讯 8月20日晚间，特宝生物发布公告称，公司第九届监事会第七次会议审议通过了《关于公 司2025年半年度报告及其摘要的议案》《关于公司2025年半年度募集资金存放与实际使用情况的专项报 告的议案》。 ...